Welcome to our dedicated page for Celularity news (Ticker: CELU), a resource for investors and traders seeking the latest updates and insights on Celularity stock.
Celularity Inc. (NASDAQ: CELU) is a regenerative and aging-related cellular medicine company whose news flow reflects developments across placental-derived biomaterial products, cell therapies, financing, and regulatory milestones. As a Nasdaq-listed issuer, Celularity regularly reports corporate updates, clinical data, partnerships, and capital markets transactions that are relevant to investors and observers of the regenerative medicine and longevity sectors.
News about Celularity often covers its advanced biomaterial products and wound care franchise, including updates on Biovance and Biovance 3L human amniotic membrane allografts and related reimbursement and coverage policies. The company has commented on Centers for Medicare & Medicaid Services decisions affecting skin substitute products and has highlighted real-world evidence from clinical use of its wound care products. These items can influence perceptions of the company’s commercial trajectory in chronic wound management.
Another key category of Celularity news involves its placenta-derived cell therapy programs, such as PDA-002. The company has announced peer-reviewed Phase 2 clinical trial results in diabetic foot ulcers complicated by peripheral artery disease and has discussed how state-level laws, particularly in Florida, may enable physician-directed use of certain stem cell therapies in orthopedics, wound care, and pain management. Such updates provide insight into the clinical and regulatory landscape for its investigational products.
Celularity’s press releases also address strategic partnerships and corporate structure. Examples include collaborations with Fountain Life in longevity-focused centers and with DefEYE, Inc. in ophthalmic biologics, as well as internal restructuring into distinct operating subsidiaries. In addition, the company reports on financings, debt restructuring, Nasdaq listing rule matters, and preferred stock or warrant issuances. For readers tracking CELU, this news page aggregates these developments so they can follow how Celularity’s placental-derived platform, commercial units, and capital structure evolve over time.
Celularity Inc. (Nasdaq: CELU) announced a study published in Frontiers in Immunology highlighting the antiviral properties of its placental-derived NK cells (CYNK-001) against influenza A virus (IAV). The research indicates that CYNK-001 targets IAV-infected cells, potentially benefiting patients with limited treatment options. Celularity's CYNK-001 is recognized as the first FDA-cleared immunotherapy for COVID-19 treatment. Annual costs associated with influenza in the U.S. are estimated at USD 10.4 billion, underscoring the need for effective antiviral therapies.
Celularity Inc. (Nasdaq: CELU) announced a Pre-Paid Advance Agreement with YA II PN, LTD for up to $150 million over 18 months. Each advance can be as much as $40 million, issued at a 2% discount with a 6% interest rate. If an outstanding balance exists, Celularity may need to sell shares at a price tied to a 135% or 95% of the VWAP, with a minimum price of $0.75. Proceeds will be used for working capital and to support R&D initiatives. The agreement is detailed in a shelf registration statement filed with the SEC.
Celularity Inc. (Nasdaq: CELU), a clinical-stage biotech firm, announced that CEO Robert Hariri will participate in investor conferences. He will engage in fireside chats at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 1:30 p.m. ET, and the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 12:20 p.m. ET. Live webcasts will be available on Celularity's website and archived for 30 days post-event.
Celularity focuses on developing placental-derived cell therapies for cancer and other diseases.
Celularity Inc. (NASDAQ: CELU) recently announced significant updates, including the treatment of the first patient in a Phase 1/2a clinical trial for CYNK-101 in advanced HER2 positive gastric cancers. The company completed a $30 million private placement and appointed Diane Parks to its Board of Directors. Financially, Celularity reported a net income of $47.8 million for Q2 2022, a substantial recovery from a $64.5 million loss in Q2 2021. Net revenues increased by $0.6 million year-on-year, driven by higher license and royalty revenues. Cash reserves stood at $38 million as of June 30, 2022.
Celularity Inc. (Nasdaq: CELU) announced the treatment of its first patient with CYNK-101, a genetically modified NK cell therapy, in a Phase 1/2a trial targeting HER2 positive gastric and gastroesophageal junction cancers. The FDA has granted both Fast Track and Orphan Drug Designations, enhancing the trial's potential for expedited review. CYNK-101 aims to synergize with existing antibody therapies, potentially improving survival rates in patients with these difficult-to-treat cancers. The trial's design includes escalating doses to determine safety and efficacy.
Celularity Inc. (Nasdaq: CELU) announced its inclusion in the Russell 3000 and Russell 2000 Indexes, effective June 27, 2022. This milestone follows Celularity's public debut last year and aims to enhance awareness of its placental-derived cell therapies. The Russell Indexes are widely used benchmarks for investment managers, encompassing approximately $12 trillion in assets. Membership signifies a broader market presence for Celularity, which develops innovative therapies targeting cancer and other diseases utilizing unique placental biology.
Celularity Inc. appointed Diane Parks to its Board of Directors, enhancing its expertise in cellular therapies. With over 30 years in the pharmaceutical sector, Parks brings a wealth of experience, having held senior roles at Kite Pharma and Amgen. Her proven track record in launching successful therapies aligns with Celularity's strategic goals. Concurrently, Jay R. Bloom has resigned from the board, marking a significant transition for the company during its growth phase.
Celularity Inc. (Nasdaq: CELU) has announced a definitive agreement with a healthcare-focused investor to sell 4,054,055 shares of its Class A common stock for $7.40 each, raising approximately $30.0 million. The deal includes warrants for an additional 4,054,055 shares at an exercise price of $8.25. The transaction, not involving a public offering, is expected to close around May 20, 2022. Celularity plans to file a registration statement with the SEC to cover the resale of shares issued, enhancing future liquidity for investors.
Celularity Inc. (Nasdaq: CELU) reported financial results for Q1 2022, highlighting a total revenue increase to $5.9 million from $2.7 million in Q1 2021. The firm is advancing its clinical trials for NK cell therapies, including CYNK-001 for acute myeloid leukemia and glioblastoma multiforme, and CYNK-101 for gastric cancer, both of which received FDA designations. R&D expenses rose to $21.7 million, and the company faced a net loss of $62.9 million, improving from $81.5 million a year earlier. Cash and equivalents increased to $48 million as of March 31, 2022.
Celularity Inc. (Nasdaq: CELU) reported significant advancements in its clinical programs for cell therapies, particularly CYNK-001 and CYNK-101, which are in ongoing Phase 1 trials for acute myeloid leukemia and HER2+ gastric cancer, respectively. Both candidates received Fast Track and Orphan Drug Designations from the FDA. The company also highlighted a 46% increase in total revenues to $21.3 million for 2021, although it posted a significant net loss of $100.1 million. Strategic partnerships were formed to expand therapeutic applications, indicating a solid growth trajectory.